Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Michele Malagola,Nicola Polverelli,Massimo Martino,Vicky Rubini,Maria Teresa Lupo Stanghellini,Francesca Patriarca,Renato Fanin,Benedetto Bruno,Luisa Giaccone, Danilo Giuseppe Faraci,Giovanni Grillo,Stefania Bramanti,Luca Castagna,Paolo Bernasconi,Anna Amelia Colombo,Marco De Gobbi,Paolo Nicoli,Annalisa Natale,Stella Santarone,Elisabetta Terruzzi

Blood（2021）

引用 0|浏览15

暂无评分

摘要

The upper age-limit for patients with hematological malignancies eligible for allo-SCT progressed to 70-75 years. As a consequence, an increase of older patients submitted to allo-SCT has been observed worldwide and in Italy as well.

查看译文

关键词

overall survival improvement,allo-sct

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要